Male Birth Control Pill Soon: End of Condoms?

The male pill YCT-529 has passed its first human safety trial, a major breakthrough in reproductive health.

Developed by YourChoice Therapeutics, YCT-529 is a non-hormonal oral contraceptive that temporarily stops sperm production by blocking the retinoic acid receptor alpha (RAR-α).

This receptor is key to vitamin A signaling for sperm development and by blocking it YCT-529 disrupts spermatogenesis without affecting testosterone or male hormones.

Unlike earlier male contraceptives that used hormones and caused side effects like mood swings, libido loss or weight gain, YCT-529 maintains hormonal balance.

This hormone-free approach will be a game changer for men.

Preclinical trials in mice and monkeys showed 99% efficacy in preventing pregnancy with full and reversible fertility restoration within weeks of stopping the drug.

Human Phase 1a trials with 16 healthy men showed the pill was well tolerated with no serious side effects or impact on libido and testosterone.

Now longer term Phase 1b/2a trials with more participants are underway to see how long YCT-529 suppresses sperm production and to monitor safety.

These trials are 28 and 90 days dosing and will confirm consistent efficacy and reversibility.

YCT-529 could be the first reliable, reversible, oral male pill, expanding family planning options beyond condoms and vasectomy.

It will promote shared contraceptive responsibility and reproductive autonomy, a major step towards gender equity in birth control.

YCT-529 is a revolutionary non-hormonal male pill that stops sperm production without hormonal side effects, with early human trial results and ongoing studies to confirm long term safety and efficacy